Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma
What is required to advance data ethics, data sharing, and Open Science across LMICs
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease
Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC
Opinion: Premature regulatory approval by the FDA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma
The future of precision oncology